NBY — NovaBay Pharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00
- $2.84m
- $2.80m
- $14.73m
- 21
- 50
- 54
- 37
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 6.94 | 12 | 7.5 | 5.36 | 3.13 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 1.07 | 1.11 | 1.67 | 1.97 | 0.759 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 9.38 | 14.2 | 13.2 | 11.3 | 7.15 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1.36 | 0.52 | 0.604 | 1.95 | 1.38 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 11.2 | 15.2 | 24 | 16.4 | 9.03 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 5.69 | 2.83 | 3.44 | 4.26 | 4.28 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 10.2 | 2.92 | 13.8 | 5.84 | 5.72 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 0.973 | 12.3 | 10.2 | 10.6 | 3.31 |
Total Liabilities & Shareholders' Equity | 11.2 | 15.2 | 24 | 16.4 | 9.03 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |